Project Grant R44CA295134
Award Date 9/18/25
Completion Date 8/31/27
Dollars Obligated $995K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Arizona, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $799,962 to Tripill Biotechnology, Corp. to develop radiolabeled PSMA agents with low salivary gland uptake for improved prostate cancer imaging and therapy. The key products and services to be delivered include: Constructing PSMA derivative compounds, such as NOTA-UNC-PSMA2, that can selectively reduce salivary gland uptake while maintaining high tumor uptake in prostate...
- This Project Grant award of $676,567.00 was provided by the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), to The Regents of the University of California, San Francisco (UCSF). The award will fund a multi-year research project to systematically test a transforming growth factor beta (TGFB) targeted theranostic radiopharmaceutical therapy approach across preclinical cancer models. The research aims to assess the biological effectiveness of...
- This $149,394 Project Grant was awarded on August 1, 2025 by the National Cancer Institute (NCI), part of the Department of Health and Human Services, under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394). The grant supports research led by the University of California, Davis to advance the development of targeted radiopharmaceuticals for cancer diagnosis and therapy. Specifically, the research focuses on designing, synthesizing, and optimizing novel molecular imaging...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development of a novel, targeted small molecule inhibitor called TRE-515 by Trethera Corp, a clinical-stage biopharmaceutical company based in California. The $1,150,000 award will fund preclinical studies to evaluate TRE-515, which targets the deoxycytidine kinase (DCK) enzyme, as a potential combination therapy to prevent the DCK-mediated resistance mechanism in...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $736,168 to the Sloan-Kettering Institute for Cancer Research to develop first-in-class antibody-drug conjugates (ADCs) and payloads specifically designed for combination with external beam radiotherapy. The key products and services to be delivered include: Developing HER2-directed ADCs containing DNA damage response inhibitors as payloads, which have demonstrated efficacy in vitro and...
- This $255,730 National Science Foundation project grant supports the development of self-assembling molecular brachytherapy for treatment of metastatic cancer. The goal is to enable radiation therapies for metastatic cancer, which accounts for approximately 90% of cancer deaths in the United States each year. The grantee, Oncurie, LLC, seeks to advance a radiotherapy approach that exploits cancer cells themselves as catalysts for therapeutic delivery. Specifically, the company will develop an...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $353,009 to Paramita Therapeutics Inc. to develop "Novel Multivalent PSMA-Targeted Taxane-Conjugates for Bone Metastases in Prostate Cancer." The project aims to synthesize and evaluate PSMA-targeted drug conjugates containing multiple copies of the taxane chemotherapies docetaxel or paclitaxel. The goal is to improve water solubility and selective targeting of prostate cancer...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports research on targeted radioimmunotherapy for glioblastoma, a highly aggressive form of brain cancer. The $432,134 award was granted on June 5, 2025 to the University of Texas MD Anderson Cancer Center. The research aims to develop an innovative treatment approach using IL13RA2, a cell surface receptor expressed on glioblastoma tumors, as a target for delivering cytotoxic radioisotopes....
- This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to support research by Oncotab, Inc. on optimized targeted radiotherapy for pancreatic cancer. The key objectives are to develop a tumor-specific antibody (HTAB004) and a tandem single-chain variable fragment (scFv) targeting agent labeled with alpha and beta particle-emitting radioisotopes. This research aims to overcome the challenge of the desmoplastic stroma in pancreatic...